Suppliers
Contact Us
![]() Voortstraat 49, 1910 Kampenhout BELGIUM Tel 0032 16 58 90 45 Fax 0032 16 50 90 45 This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it. |
GENTAUR BULGARIA
53 Iskar Str. 1191 Kokalyane, Sofia
Tel 0035924682280
Fax 0035929830072
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50
Fax 01 43 25 01 60
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
GmbH Marienbongard 20
52062 Aachen Deutschland
Tel (+49) 0241 56 00 99 68
Fax (+49) 0241 56 00 47 88 This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-family: Arial, Tahoma, Verdana, Helvetica; line-height: 15.59375px; ">
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-size: 12px; line-height: 1.3em;">
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531
Fax 020 8445 9411
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR Nederland BV
Kuiper 1
5521 DG Eersel Nederland
Tel 0208-080893
Fax 0497-517897
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93
Fax 02 36 00 65 94
This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR Spain
Tel 0911876558
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
Phone/Fax:
(408) 780-0908
This email address is being protected from spambots. You need JavaScript enabled to view it.
GENPRICE Inc. invoicing/ accounting:
6017 Snell Ave, Suite 357
San Jose, CA. 96123
Serbia,
Macedonia,
Montenegro,
Croatia:
Tel 0035929830070
Fax 0035929830072
This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR Romania
Tel 0035929830070
Fax 0035929830072
This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR Greece
Tel 00302111768494
Fax 0032 16 50 90 45
This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.
Other countries
Luxembourg +35220880274
Schweiz Züri +41435006251
Danmark +4569918806
Österreich +43720880899
Ceská republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Magyarország Budapest +3619980547
Primary and secondary antibodies for plant and algal cell biology
Antibodies for :
Arabidopsis thaliana, Chlamydomonas sp. , diatoms, Hordeum vulgare, Nicotiana tabacum, Oryza sativa, Physcomitrella patens, Pisum sativum, Populus sp., Spinacia oleracea, Synechococcus sp., Zea mays. And many more!
For: western blot, immunolocalizations, IP
Speed up Your research with the most comprehensive plant and algal antibody collection from original manufacturer
All antibodies are carefully validated by our own testing laboratory or in collaboration with scientists in the field.
Contact us and we will help you to find the right antibody for your application!
p40 Antibody
The p40 antibody, catalog number A00112 is provided in concentrated form or in ready-to-use as a 2ml, 7ml, or 25ml. This antibody is very important as it is helpful in the indication of several different carcinomas and has a wide-spread use in the market. We have developed the p40 antibody as a replacement antibody for the p63 antibody. The marker is highly specific for squamous basal cells and is more specific than the p63 marker. One of the most important functions of this antibody is the ability to differentiate between adeno carcinoma and squamous cell carcinoma for lung cancer. As you are aware the difference between those carcinomas will determine what avenue of treatment will be applied. The p40 is specific for indication of the squamous cell carcinoma. We will soon be releasing our Napsin A antibody for the adeno carcinoma. These two antibodies work well in conjunction with one another and they will help the pathologist determine what method of treatment is necessary.
The p40 is also an excellent antibody in the use of prostate cancer. In the early stages of prostate cancer the basal cells inside the ducts will be stained by the p40. This will help indicate the prostatic intraepithelial neoplasia (PIN) that is considered to be a pre-malignancy as it is a carcinoma in situ of the prostatic glands. As the cancer progresses the basal cells will be seen throughout the tissue as the cells become invasive. This antibody can help determine the stage of carcinoma by indicating locations of the basal cells that are stained.
The p40 antibody is also being used with breast cancer as the antibody will stain myoepithelial cells along the ducts of the mammary glands. This antibody is excellent in determining if Atypical ductal hyperplasia (ADH) is present which can indicate a risk factor for breast cancer and serves as early detection of breast cancer. This marker will also indicate Ductal Carcinoma in Situ (DCIS) similar to the way it works on prostate cancer. This is the most common non-invasive type of breast cancer. The marker will indicate DCIS by highlighting that the cells are still within the ducts. As breast cancer progresses and becomes invasive those ducts will breakdown and the myoepithelial cells will be seen throughout the tissue and become Invasive Ductal Carcinoma (IDC).
p40 (p63 Delta); Polyclonal (Ready-To-Use)
Species: Rabbit
Clone: Polyclonal
Isotype: Rabbit IgG
Species Reactivity: Human.
Cellular Localization: Nuclear.
Specificity: The new marker p40 (p63 delta) is highly specific for squamous basal cells.
p40 (p63 Delta); Polyclonal (Concentrate)
Species: Rabbit
Clone: Polyclonal
Isotype: Rabbit IgG
Species Reactivity: Human.
Cellular Localization: Nuclear.
Specificity: The new marker p40 (p63 delta) is highly specific for squamous basal cells.
New Subspecialty Proposed for Patients with Depression and Heart Disease
In his most recent study, Angelos Halaris, MD, PhD, and colleagues found that an inflammatory biomarker, interleukin-6, was significantly higher in the blood of 48 patients diagnosed with major depression than it was in 20 healthy controls. Interleukin-6 has been associated with cardiovascular disease. Halaris presented findings at a joint congress of the World Psychiatric Association and International Neuropsychiatric Association in Athens, Greece. At the congress, Halaris formally proposed creation of a new Psychocardiology subspecialty.
Forty to 60 percent of heart disease patients suffer clinical depression and 30 to 50 percent of patients who suffer clinical depression are at risk of developing cardiovascular disease, Halaris said.
Stress is the key to understanding the association between depression and heart disease. Stress can lead to depression, and depression, in turn, can become stressful.
The body’s immune system fights stress as it would fight a disease or infection. In response to stress, the immune system produces proteins called cytokines, including interleukin-6. Initially, this inflammatory response protects against stress. But over time, a chronic inflammatory response can lead to arteriosclerosis (hardening of the arteries) and cardiovascular disease.
It’s a vicious cycle: depression triggers a chronic inflammation, which leads to heart disease, which causes depression, which leads to more heart disease.
Clinical depression typically begins in young adults. “Treating depression expertly and vigorously in young age can help prevent cardiovascular disease later on,” Halaris said.
Physicians often work in isolation, with psychiatrists treating depression, and cardiologists treating cardiovascular disease. Halaris is proposing that psychiatrists and cardiologists work together in a multidisciplinary Psychocardiology subspecialty.
A Psychocardiology subspecialty would raise awareness among physicians and the public. It would forge closer working relationships between psychiatrists and cardiologists. It would formalize multidisciplinary teams with the requisite training and expertise to enable early detection of cardiovascular disease risk in psychiatric patients and psychiatric problems in heart disease patients. And it would provide continuing education to physicians in the safe and correct use of medications in cardiac patients who have psychiatric disorders.
“It is only through the cohesive interaction of such multidisciplinary teams that we can succeed in unravelling the complex relationships among mental stress, inflammation, immune responses and depression, cardiovascular disease and stroke,” Halaris said.
Halaris is Medical Director of Adult Psychiatry and a Professor in the Department of Psychiatry and Behavioral Neurosciences at Loyola University Chicago Stritch School of Medicine.
Could Cancer Sore Drug Be the Next Weight Loss Miracle Pill?
A drug currently approved to treat mouth ulcers has shown promise in animal studies for being a contender in pharmaceutical weight loss. Amlexanox was found by University of Michigan researchers to produce weight loss in obese mice without any change in diet or exercise habits.
For the study, mice fed a high calorie diet until they became obese were injected with amlexanox. The animals lost weight, despite consuming the same amount of calories. The researchers also noted a loss in overall body fat, a decrease in fatty liver, and a reversal of obesity-induced type 2 diabetes. Once taken off the amlexanox injections, however, the mice experienced weight gain.
Amlexanox may work by changing the action of genes that control metabolism versus working as an appetite suppressant.
When the drug was injected in mice, the drug worked by increasing metabolism, not by suppressing appetite.
"One of the reasons that diets are so ineffective in producing weight loss for some people is that their bodies adjust to the reduced calories by also reducing their metabolism, so that they are 'defending' their body weight," says Dr. Alan Saltiel, the lead researcher at the University of Michigan.
"Amlexanox seems to tweak the metabolic response to excessive calorie storage in mice."
The findings were published Sunday in the journal Nature Medicine. Clinical trials are expected to begin later this year to test the drug's effectiveness in humans.
Heat Block Incubator
WSC-2610 MyMiniBLOCK
Do you need only heating function with block incubator? WSC-2610 MyMiniBLOCK is a microprocessor-controlled product using advanced thermoelectric technology. With this technique, more stable and accurate up to 100 C temperature control is achieved. In compact body, very various use such as sample preparation of electrophoresis, DNA/RNA denature and reaction, trans-information of E. coli, etc. can be applied.
WSC-2620 PowerBLOCK
WSC-2620 PowerBLOCK is able to reach set-temperature in mins.
It can reach to the target temperature in about 7min, you can easily use it with different temperature just after using with previously set temperature. Wide and stably accurate temperature setting is from –10 to 100o C. It can be used for very wide applications and used in different temperature settings continuously.
WSC-2630 PowerBLOCK Shaker
PowerChek™ Animal Species ID Real-time PCR Kits
Characteristics
· Detection kit for Animal Species
· Real-time PCR based on TaqMan™ probe-based technology
· Rapid & simple reaction
· No contamination : closed system
· No error : Internal positive control
· Easy to operation in less than 2.5 hrs
Kit Components
· Primer/probe mixture
· 2X Real-time PCR Master Mix
· Control
Protocol
After DNA Ext.
· Step 1 : Mix extracted DNA with the Kit’s reagents
· Step 2 : Real-time PCR run
· Step 3 : Analysis
Exp
Products:
R0406 |
PowerChekTM Horse species Real-time PCR Kit Fluorephore: FAM |
50 rxn |
383-Eur |
R0406E |
PowerChekTM Horse species Real-time PCR Kit with EPC Fluorephore: FAM, HEX(VIC) |
50 rxn |
441-Eur |
NEPTUNE Barrier Tips 10 ul XL Low Retentio
Quantity: 4800 (in case - Racked - 96)
Availability: Yes
Details:
Barrier Tips to Give You Complete Peace of Mind
Protect your work from contamination with one of the industry’s most efficient aerosol filter assemblies. Our proven range of barrier tips reliably prevent aerosol transfer to give you complete peace of mind when performing your most sensitive assays.
BT10XL Series - 10 µl Extended Length Barrier Tip
GENTAUR offers a complete selection of high quality pipet tips for your entire laboratory's needs.
Specifications:
* GLP Compliance Certified
* S³ Low retention Polymer Technology
* No detectable nucleic acid
* No detectable endotoxin
* No detectable endonucleases
* No detectable PCR inhibitors
* Pre-sterilized
* NEPTUNE S³ Tip without any residue
* Non S³ Tip with sample residue
S3 Low Retention Polymer Technology for Total Sample Recovery.
Exclusively form CLP!
The trend in research toward ever smaller reaction volumes has many benefits, including improved reaction kinetics, more consistent results and lower overall costs. However, low volume techniques require dispensing very small volumes of reagents with high degree of accuracy and consistency
Pipet tips produced from standard polymers will variably retain biological solutions, preventing accurate and repeatable results. Diamond polishing of the mold reduces the number of imperfections producing a smoother surface. Silicone treatment of tips further reduces retention, but can leach out and interfere with reactions, or degrade at autoclaving temperatures.
CLP was the first company to address this challenge and develop a novel polymer technology that produces a Super Slick Surface S3 on plastics. Traditionally, small occlusions and cavities within the molded plastic resulted in significant sample loss. Our third generation S3 polymer system results in a microscopically uniform surface, which virtually eliminates sample hold-up providing the most accurate sample delivery possible. CLP’s S3 polymer combined with our advanced production process produces the most consistent low retention plastics in the industry.
Prices:
1 box 10x96 Tips for 59 EUR
10boxes 10x96 Tips + 1 labpet of choice for 480 EUR
20boxes 10x96 Tips+ 3 labpets for 880 EUR
30boxes 10x96Tips + 5 labpets for 1290 EUR
*1250ul are 8x96 in a box
Combination of two antibodies prevents growth and spread of triple-negative breast tumors
Cancer drugs of the new, molecular generation destroy malignant breast tumors in a targeted manner: They block characteristic molecules on tumor cells - receptors for the hormones estrogen or progesterone, or a co-receptor, called HER2, that binds to many growth factors. But about one in every six breast tumors has none of these receptors. Such cancers, called triple-negative, are particularly aggressive and notoriously difficult to treat.
Some of these therapy-resistant cancers have a potential molecular target for cancer drugs, a growth-factor receptor called EGFR, but an EGFR-blocking drug has proved ineffective in treating them. In a study published recently in the Proceedings of the National Academy of Sciences, Weizmann Institute researchers propose a potential solution: to simultaneously treat triple-negative breast cancer with two EGFR-blocking antibodies instead of one. In a study in mice, the scientists showed that a certain combination of two antibodies indeed prevented the growth and spread of triple-negative tumors. The research team, led by Prof. Yosef Yarden of the Biological Regulation Department and Prof. Michael Sela of the Immunology Department, included Drs. Daniela Ferraro, Nade`ge Gaborit, Ruth Maron, Hadas Cohen-Dvashi, Ziv Porat, Fresia Pareja, and Sara Lavi, Dr. Moshit Lindzen and Nir Ben-Chetrit.
Of the different combinations they tried, the scientists found that the approach worked when the two antibodies bound to different parts of the EGFR molecule. The combined action of the antibodies was stronger than would have been expected by simply adding up the separate effects of each. Apparently, the use of the two antibodies created an entirely new anti-cancer mechanism: In addition to blocking the EGFR and recruiting the help of immune cells, the antibodies probably overwhelmed the EGFR by their sheer weight, causing it to collapse inward from the membrane into the tumor cell.
Deprived of EGFR on its surface, the cells were no longer receiving the growth signals, preventing the growth of the tumor. This approach resembles the natural functioning of the immune system, which tends to block essential antigens at several sites by targeting them with multiple antibodies. If supported by further studies, the two-antibody approach, in combination with chemotherapy, might in the future be developed into an effective treatment for triple-negative breast cancer.
Genetically Modified Tobacco Plants Produce Antibodies to Treat Rabies
Smoking tobacco might be bad for your health, but a genetically altered version of the plant might provide a relatively inexpensive cure for the deadly rabies virus. In a new research report appearing in The FASEB Journal, scientists produced a monoclonal antibody in transgenic tobacco plants that was shown to neutralize the rabies virus. This new antibody works by preventing the virus from attaching to nerve endings around the bite site and keeps the virus from traveling to the brain.
"Rabies continues to kill many thousands of people throughout the developing world every year and can also affect international travelers," said Leonard Both, M.Sc., a researcher involved in the work from the Hotung Molecular Immunology Unit at St. George's, University of London, in the United Kingdom. "An untreated rabies infection is nearly 100 percent fatal and is usually seen as a death sentence. Producing an inexpensive antibody in transgenic plants opens the prospect of adequate rabies prevention for low-income families in developing countries."
To make this advance, Both and colleagues "humanized" the sequences for the antibody so people could tolerate it. Then, the antibody was produced using transgenic tobacco plants as an inexpensive production platform. The antibody was purified from the plant leaves and characterized with regards to its protein and sugar composition. The antibody was also shown to be active in neutralizing a broad panel of rabies viruses, and the exact antibody docking site on the viral envelope was identified using certain chimeric rabies viruses.
"Although treatable by antibodies if caught in time, rabies is bad news," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "This is especially true for people in the developing world where manufacturing costs lead to treatment shortages. Being able to grow safe, humanized antibodies in genetically modified tobacco should reduce costs to make treatments more accessible, and save more lives."